Scynexis (SCYX) Cash from Investing Activities (2013 - 2026)
Scynexis (SCYX) reported Cash from Investing Activities of -$525000.0 for Q1 2026, down 104.22% on a YoY basis from $12.4 million in Q1 2025, and up 95.56% quarter-over-quarter from -$11.8 million in Q4 2025.
Scynexis (SCYX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Scynexis has reported Cash from Investing Activities for 14 years, with the latest figure at -$525000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 104.22% year-over-year to -$525000.0; the trailing twelve-month figure through Mar 2026 stood at $11.3 million (down 13.66% YoY), and the FY2025 full-year result was $24.3 million, up 295.22% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$525000.0, up from -$11.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $12.4 million in Q1 2025, with the low at -$27.4 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged -$2.3 million across 5 years, with a median of -$267000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 8000.59% — and 2025, when it surged 721.65%.
- Scynexis' Cash from Investing Activities stood at -$27.4 million in 2022, then surged by 92.14% to -$2.2 million in 2023, then dropped by 21.61% to -$2.6 million in 2024, then tumbled by 351.82% to -$11.8 million in 2025, then jumped by 95.56% to -$525000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$525000.0 (Q1 2026), -$11.8 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 25.99 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -15.45 Mn |
| 10 | Scynexis | 216.06 Mn | 156.80 Mn | - | -525,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -525,000.00 |
| Mar 31, 2026 | -525,000.00 |
| Dec 31, 2025 | -11.82 Mn |
| Dec 31, 2025 | -11.82 Mn |
| Sep 30, 2025 | 12.42 Mn |
| Sep 30, 2025 | 12.42 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Mar 31, 2025 | 12.44 Mn |
| Mar 31, 2025 | 12.44 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Dec 31, 2024 | -2.62 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 5.45 Mn |
| Mar 31, 2024 | 5.45 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Dec 31, 2023 | -2.15 Mn |